why choose us

300×250 Ad Slot

Drug FDA Status

Showing 80 of 144 result(s) (Page 8 of 15)
Drug Name: Sofdra

Active Ingredient: sofpironium

Approval Date: 2024-06-18

Description: To treat primary axillary hyperhidrosis
Drug Trials Snapshot

Drug Name: Iqirvo

Active Ingredient: elafibranor

Approval Date: 2024-06-10

Description: To treat primary biliary cholangitis in combination with ursodeoxycholic acid
Drug Trials Snapshot

Drug Name: Rytelo

Active Ingredient: imetelstat

Approval Date: 2024-06-06

Description: To treat low- to intermediate-1 risk myelodysplastic syndromes
Drug Trials Snapshot

Drug Name: Imdelltra

Active Ingredient: tarlatamab-dlle

Approval Date: 2024-05-16

Description: To treat extensive stage small cell lung cancer
Drug Trials Snapshot

Drug Name: Xolremdi

Active Ingredient: mavorixafor

Approval Date: 2024-04-26

Description: To treat WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis)
Drug Trials Snapshot

Drug Name: Ojemda

Active Ingredient: tovorafenib

Approval Date: 2024-04-23

Description: To treat relapsed or refractory pediatric low-grade glioma
Drug Trials Snapshot

Drug Name: Anktiva

Active Ingredient: nogapendekin alfa inbakicept-pmln

Approval Date: 2024-04-22

Description: To treat bladder cancer
Drug Trials Snapshot

Drug Name: Lumisight

Active Ingredient: pegulicianine

Approval Date: 2024-04-17

Description: To use as an optical imaging agent for the detection of cancerous tissue
Drug Trials Snapshot

Drug Name: Zevtera

Active Ingredient: ceftobiprole medocaril sodium

Approval Date: 2024-04-03

Description: To treat certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumonia
Press Release
Drug Trials Snapshot

Drug Name: Voydeya

Active Ingredient: danicopan

Approval Date: 2024-03-29

Description: To treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuria
Drug Trials Snapshot

300×250 Ad Slot